Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Hemophilia A
Interventions
BIOLOGICAL

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.

Trial Locations (5)

100730

Beijing

430022

Wuhan

510515

Guangzhou

Unknown

Beijing

Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY